

Appendix 2: Evidence Tables

I. On demand PPI vs Continuous PPI for maintenance therapy of reflux esophagitis and gastroesophageal reflux disease?¹

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	On demand PPI	Continuous PPI	Relative (95% CI)	Absolute		
Lack of Symptom Control [1–5]												
5 ^{2,3}	randomised trials	serious ⁴	no serious inconsistency	no serious indirectness	serious ⁵	none	140/859 (16.3%)	73/794 (9.2%)	RR 1.71 (1.31 to 2.21)	7% (3 to 11%)	⊕⊕⊕⊕ LOW	
Pill Use (tablets/week) (Better indicated by lower values) [1,2,5]												
3 ⁶	randomised trials	serious ⁷	no serious inconsistency ⁸	no serious indirectness	no serious imprecision	none	571	581	-	MD 3.79 lower (4.73 to 2.84 lower)	⊕⊕⊕⊕ MODERATE	
Satisfaction (unwilling to continue or inadequate relief) [1–5]												
5	randomised trials	serious ⁹	no serious inconsistency	serious ¹⁰	serious ¹¹	none	136/859 (15.8%)	70/794 (8.8%)	RR 1.82 (1.26 to 2.65)	7% (2 to 14%)	⊕⊕⊕⊕ VERY LOW	

¹ Four studies used maintenance dose PPI on-demand (pantoprazole 20 mg/rabeprazole 10 mg/esomeprazole 20mg) while one study used healing dose PPI on-demand (pantoprazole 40 mg)

² Four studies did not report endoscopic findings

³ Lack of symptom control defined as inadequate symptom relief or treatment failure (return of symptom(s) of at least moderate severity or symptoms incompatible with well-being)

⁴ No low risk of bias trials (all studies with high risk of detection bias, three of five with high risk of attrition bias)

⁵ 95% CI wide and close to line of no effect

⁶ Studies used maintenance dose PPI on-demand (pantoprazole 20mg/rabeprazole 10 mg/esomeprazole 20mg)

⁷ No low risk of bias trials (all three studies at high risk of detection and attrition bias)

⁸ Statistically significant heterogeneity but not clinically important as all trials showed strong statistically significant benefit

⁹ No low risk of bias trials (four studies at high risk of attrition and reporting bias)

¹⁰ Evidence indirect as poor methods of satisfaction used (willingness to continue or "inadequate relief")

¹¹ 95% CI wide and close to line of no effect (for willingness to continue the result was not statistically significant)

II. Maintenance dose PPI vs Healing dose PPI for maintenance therapy of reflux oesophagitis and gastroesophageal reflux disease

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Maintenance dose PPI	Healing dose PPI	Relative (95% CI)	Absolute		
Oesophagitis relapse (endoscopic findings) [6–11]												
6	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision ²	none	228/916 (24.9%)	186/1191 (15.6%)	RR 1.54 (1.25 to 1.89)	8% (4 to 14%)	⊕⊕⊕O MODERATE	
Symptom relapse [6–10]												
5 ^{3,4}	randomised trials	serious ¹	serious ⁵	no serious indirectness	no serious imprecision	none	343/810 (42.3%)	470/1102 (42.6%)	RR 1.16 (0.93 to 1.44)	7% (-3 to 19%)	⊕⊕OO LOW	^{3,4}

¹ No low risk of bias trials (most trials had unclear risk of bias)

² 95% CI narrow and in favour of healing dose PPI, close to line of no effect

³ Studies did not measure patient satisfaction

⁴ Symptom relapse defined as return of symptom(s) of at least moderate severity(enough to interfere with normal activity) for three to seven consecutive days in five studies and return of symptom(s) of any severity in one study

⁵ Statistically significant heterogeneity that was unexplained

III. H2 receptor antagonist vs Healing dose PPI for maintenance therapy of reflux esophagitis and gastroesophageal reflux disease¹

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	H2 receptor antagonist	Healing dose PPI	Relative (95% CI)	Absolute		
Esophagitis relapse (endoscopic findings) [7,12,13]												
3	randomised trials	serious ²	no serious inconsistency ³	no serious indirectness	no serious imprecision	none	121/242 (50%)	36/242 (14.9%)	RR 3.52 (1.8 to 6.87)	37% (12 to 87%)	⊕⊕⊕O MODERATE	
Symptom relapse [7,12,13]												
3 ^{4,5}	randomised trials	serious ²	no serious inconsistency	no serious indirectness	no serious imprecision ⁶	none	91/232 (39.2%)	49/236 (20.8%)	RR 1.92 (1.44 to 2.58)	19% (9 to 33%))	⊕⊕⊕O MODERATE	

¹ H2RA likely to increase pill burden as typically dosed twice daily

² No low risk of bias trials (most studies had unclear risk of bias)

³ Statistically significant heterogeneity but not clinically important as all trials showed strong statistically significant benefit of standard dose PPI

⁴ Studies did not measure patient satisfaction

⁵ Symptom relapse defined as return of symptom(s) of at least moderate severity in two studies and at least mild severity in one study

⁶ 95% CI narrow and in favour of healing dose PPI

IV. Abrupt discontinuation of PPI vs. continuation of PPI for maintenance therapy of reflux esophagitis and gastroesophageal reflux disease

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Deprescribing	Continued Use	Relative (95% CI)	Absolute		
Lack of Symptom Control - Symptom Relapse Rate [14]												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	38/56 (67.9%)	11/49 (22.4%)	RR 3.02 (1.74 to 5.24)	453 more per 1000 (from 166 more to 952 more)	⊕○○○ VERY LOW	
								22.5%		454 more per 1000 (from 167 more to 954 more)		
Adverse Drug Withdrawal Events (ADWE) - Relapse (Endoscopic Findings) [14]												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	39/56 (69.6%)	10/49 (20.4%)	RR 3.41 (1.91 to 6.09)	492 more per 1000 (from 186 more to 1000 more)	⊕○○○ VERY LOW	
								20.4%		492 more per 1000 (from 186 more to 1000 more)		

¹ Concerns surrounding attrition bias and blinding

² 95% CI wide, number of participants and events small

References:

1. Bour B, Staub J-L, Chousterman M, Labayle D, Nalet B, Nouel O, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. *Aliment Pharmacol Ther.* 2005 Apr;21(7):805–12.
2. Janssen W, Meier E, Gatz G, Pfaffenberger B, Pfivate I. Effects of Pantoprazole 20 mg in Mild Gastroesophageal Reflux Disease : Once-Daily Treatment in the Acute Phase , and Comparison of On-Demand Versus Continuous Treatment in the Long Term. 2005;66(4):345–63.
3. Morgan DG, O'Mahony MFJ, O'Mahony WF, Roy J, Camacho F, Dinniwell J, et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. *Can J Gastroenterol.* 2007 Dec;21(12):820–6.
4. van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. *Digestion.* 2010;81:43–52.
5. Bayerdörffer E, Bigard M-A, Weiss W, Mearin F, Rodrigo L, Dominguez Muñoz JE, et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. *BMC Gastroenterol* [Internet]. 2016 Dec 14;16(1):48. Available from: <http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0448-x>
6. Escourrou J, Deprez P, Saggioro a, Geldof H, Fischer R, Maier C. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. *Aliment Pharmacol Ther.* 1999 Nov;13(11):1481–91.
7. Gough a L, Long RG, Cooper BT, Fosters CS, Garrett a D, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. *Aliment Pharmacol Ther.* 1996 Aug;10(4):529–39.
8. Plein K, Hotz J, Wurzer H, Fumagalli I, Luhmann R SA. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. *Eur J Clin Pharmacol.* 2000;12:425–32.
9. Baldi F, Bardhan K, Borman B, Brullet E, Dent J, Galmiche J, et al. Lansoprazole maintains healing in patients with reflux esophagitis. *Gastroenterology.* 1996;(110):A55.
10. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. *Aliment Pharmacol Ther* [Internet]. 1997 Apr;11(2):365–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9146777>
11. Poynard T, Staub J, Lemerez M, Deltenre M, Rekacevicz C, Sallerin V. Efficacy and safety of lansoprazole 15 mg oad or 30mg oad as one year maintenance treatment for erosive reflux esophagitis. A randomized trial. *Gastroenterology* [Internet]. 1995 Apr;108(4):A195. Available from: <http://linkinghub.elsevier.com/retrieve/pii/0016508595234411>
12. Annibale B, Franceschi M, Fusillo M, Beni M, Cesana B DFG. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. *Hepatogastroenterology.* 1998;45:742–51.
13. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. *Gut* [Internet]. 1994 May 1;35(5):590–8. Available from: <http://gut.bmj.com/cgi/doi/10.1136/gut.35.5.590>
14. Pilotto A, Ndro GLEA, Anceschi MFR, Alf BEH, The OF, Eing AG, et al. Short- and long-term therapy for reflux oesophagitis in the elderly : a multi-centre , placebo-controlled study with pantoprazole. 2003;1399–406.